Spread of cancer cells may be slowed by targeting of protein

(Medical Xpress)—The spread of cancer cells may be slowed by targeting the protein km23-1, according to researchers at Penn State College of Medicine.

A motor protein that transports cargo within the cell, km23-1 is also involved in the movement or migration of cells. Migration is necessary for cancer to spread, so understanding this cell movement is important for development of better cancer treatments.

Kathleen Mulder, Ph.D., professor, biochemistry and molecular biology, looked for partner proteins that bind to and cooperate with km23-1 during cell movement, whichturned out to include factors that can control proteins actin and RhoA.

" is an important aspect of the process of a tumor spreading," Mulder said. "Changes in this process transform from local, noninvasive, confined cells to the migrating, cells."

Cells move through the body using the protein actin, which forms the structural frame of the cell, called the cytoskeleton. The actin creates a protrusion in the cell membrane by forming strands of thread-like fibers on the leading edge of the cell, pushing the cell forward. Several identified proteins regulate the reorganization of the and are more active in several types of cancers.

Overexpression of km23-1 increases actin , whereas when km23-1 is diminished, RhoA activity decreases. RhoA is known to be an important switch, activating processes in migration.

"By knowing that RhoA activity was decreased when km23-1 was reduced, we infer that km23-1 is needed for the regulation of these switches and has a role in cell movement," Mulder said.

To test this in the lab, km23-1 was reduced in a sample of human . When km23-1 was diminished, cancer cells migrated less. More research needs to be done, but km23-1 may be a promising target for anti-metastatic drugs and cancer therapies to slow the spread of the disease.

"By inhibiting km23-1, you inhibit events that contribute to the cells spreading to other parts of the body," Mulder said.

Results were reported in Biochemical and Biophysical Research Communications.

Other researchers are Qunyan Jin, Nageswara R. Pulipati, Cory M. Staub, of the Department of Biochemistry and Molecular Biology, Penn State College of Medicine; and Weidong Zhou and Lance A. Liotta, Center for Applied Proteomics and Molecular Medicine, George Mason University.

Funding was provided by the National Institutes of Health.

Related Stories

Motor protein may offer promise in ovarian cancer treatment

Apr 26, 2011

(Medical Xpress) -- A motor regulatory protein can block human ovarian tumor growth, leading to eventual cancer cell death and possible new therapies to treat the disease, according to Penn State College of Medicine researchers.

Understanding the migration of cancer cells

Jun 23, 2008

[B]Activity of regulatory proteins for the growth of filopodia and lamelopodia clarified[/B] Lamellipodia are veil-shaped protrusions of the plasma membrane, that can turn into upward-curled ruffles if they fail to adhere to ...

Recommended for you

New breast cancer imaging method promising

38 minutes ago

The new PAMmography method for imaging breast cancer developed by the University of Twente's MIRA research institute and the Medisch Spectrum Twente hospital appears to be a promising new method that could ...

Palliation is rarely a topic in studies on advanced cancer

1 hour ago

End-of-life aspects, the corresponding terminology, and the relevance of palliation in advanced cancer are often not considered in publications on randomized controlled trials (RCTs). This is the result of an analysis by ...

Breast cancer replicates brain development process

1 hour ago

New research led by a scientist at the University of York reveals that a process that forms a key element in the development of the nervous system may also play a pivotal role in the spread of breast cancer.

Is genetic instability the key to beating cancer?

3 hours ago

Cancerous tumors may be poised at the edge of their own destruction, an insight that could help researchers find new, more effective treatments, suggest SFI External Professor Ricard Solé and colleagues in an April 9 paper ...

Phase 3 study may be game-changer for acute myeloid leukemia

6 hours ago

Moffitt Cancer Center researchers say clinical trials for a new experimental drug to treat acute myeloid leukemia (AML) are very promising. Patients treated with CPX-351, a combination of the chemotherapeutic drugs cytarabine ...

User comments